新型冠状病毒感染者和灭活疫苗受种者抗体水平研究  

Study on specific antibodies in patients infected with SARS-CoV-2 and recipients of inactivated vaccine

作　　者：徐娜妮[1] 喻剑华 胡小炜[3] 李海燕 郑琳[3] 孔庆鑫[5] 叶非 李静[3] 覃盼 Xu Nani;Yu Jianhua;Hu Xiaowei;Li Haiyan;Zheng Lin;Kong Qingxin;Ye Fei;Li Jing;Qin Pan(Department of Immunization Program,Hangzhou Xihu District Center for Disease Control and Prevention,Hangzhou 310030,China;Hangzhou Xixi Hospital,Hangzhou 310023;Hangzhou Xihu District Center for Disease Control and Prevention,Hangzhou 310030,China;Hangzhou Di′an Medical Laboratory Co.,Ltd,Hangzhou 310012,China;Hangzhou Center for Disease Control and Prevention,Hangzhou 310021,China;Department of Prevention and Health,Hangzhou Xixi Hospital,Hangzhou 310023,China)

机构地区：[1]杭州市西湖区疾病预防控制中心免疫规划科,杭州310030 [2]杭州市西溪医院,杭州310023 [3]杭州市西湖区疾病预防控制中心,杭州310030 [4]杭州迪安医学检验中心有限公司,杭州310012 [5]杭州市疾病预防控制中心,杭州310021 [6]杭州市西溪医院防保科,杭州310023

出　　处：《中华微生物学和免疫学杂志》2022年第1期16-22,共7页Chinese Journal of Microbiology and Immunology

基　　金：2021年浙江省重点研发计划应急攻关项目(2021C03200);杭州市新型冠状病毒感染的肺炎防治科研攻关项目(20202013A02);杭州市科技发展计划项目(20201203B27)。

摘　　要：目的:通过观测不同时期新型冠状病毒(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)感染者和SARS-CoV-2灭活疫苗受种者血清病毒特异性IgM和IgG抗体水平,增进对SARS-CoV-2和SARS-CoV-2灭活疫苗进入机体后免疫学特征的了解。方法:选取44名COVID-19确诊病例、118名SARS-CoV-2无症状感染者和273名SARS-CoV-2灭活疫苗受种者纳入观测,分别收集检测不同时期的血清样本144份、381份和398份,化学发光免疫分析法检测SARS-CoV-2 IgM和IgG抗体水平,结合人群基本特征和疫苗接种情况进行分析。结果:确诊病例、无症状感染者和疫苗受种者IgM抗体阳性率分别为52.27%(23/44)、23.73%(28/118)和14.29%(39/273),确诊病例高于无症状感染者和疫苗受种者(χ^(2)=12.106,P=0.001;χ^(2)=34.755,P<0.001);IgG抗体阳性率分别为100.00%(44/44)、97.46%(115/118)和98.81%(166/168),差异无统计学意义(χ^(2)=2.944,P=0.229)。确诊病例中,<40岁人群的IgM抗体浓度低于≥40岁人群(Wald χ^(2)=6.609,P=0.010),有SARS-CoV-2疫苗接种史人群的IgG抗体浓度高于无接种史人群(Wald χ^(2)=12.402,P<0.001);无症状感染者中,有SARS-CoV-2疫苗接种史人群的IgG抗体浓度高于无接种史人群(Wald χ^(2)=4.530,P=0.033);疫苗受种者中,<40岁人群的IgG抗体浓度高于≥40岁人群(Wald χ^(2)=9.565,P=0.002)。抗体水平动态分析显示,从第1周到第9周,确诊病例的IgM和IgG抗体浓度高于无症状感染者和疫苗受种者。结论:确诊病例的IgM和IgG抗体水平高于无症状感染者和疫苗受种者,≥40岁的确诊病例体内IgM抗体水平较高,有SARS-CoV-2疫苗接种史的确诊病例和无症状感染者IgG抗体水平较高;SARS-CoV-2灭活疫苗全程接种后具备较好的免疫原性,<40岁的疫苗受种者体内IgG抗体水平较高。Objective To detect the serum levels of SARS-CoV-2-specific IgM and IgG antibodies in patients infected with SARS-CoV-2 and recipients of inactivated vaccine in different periods for understanding their variation patterns in vivo.Methods Chemiluminescence immunoassay was used to detect the levels of SARS-CoV-2-specific IgM and IgG antibodies in 144 serum samples of 44 COVID-19 patients,381 serum samples of 118 asymptomatic infected cases and 398 serum samples of 273 inactivated vaccine recipients collected at different periods.The results were statistically analyzed together with basic characteristics and vaccination status.Results The positive rates of IgM antibody in COVID-19 patients,asymptomatic infected cases and inactivated vaccine recipients were 52.27%(23/44),23.73%(28/118)and 14.29%(39/273).The positive rate of IgM antibody was higher in COVID-19 patients than in asymptomatic infected cases and vaccine recipients(χ^(2)=12.106,P=0.001;χ^(2)=34.755,P<0.001).The positive rates of IgG antibody in the three populations were 100.00%(44/44),97.46%(115/118)and 98.81%(166/168),and the differences were not statistically significant(χ^(2)=2.944,P=0.229).In COVID-19 patients,the concentration of IgM antibody in<40 years old group was lower than that in≥40 years old group(Waldχ^(2)=6.609,P=0.010),and the concentration of IgG antibody in patients with vaccination was higher than that in patients without vaccination(Waldχ^(2)=12.402,P<0.001).In asymptomatic infected cases,the concentration of IgG antibody was higher in people with vaccination than in those without vaccination(Waldχ^(2)=4.530,P=0.033).In SARS-CoV-2 vaccine recipients,the concentration of IgG antibody in<40 years old group was higher than that in≥40 years old group(Waldχ^(2)=9.565,P=0.002).Dynamic analysis of antibody levels showed that from week 1 to week 9,the concentrations of IgM and IgG antibodies in COVID-19 patients were higher than those in asymptomatic infected cases and vaccine recipients.Conclusions The concentrations of IgM and IgG

关 键 词：COVID-19 特异性抗体 化学发光免疫法 

分 类 号：R563.1[医药卫生—呼吸系统] R446.6[医药卫生—内科学]